EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2026

  • ID: 4434293
  • Drug Pipelines
  • 38 pages
  • GlobalData
1 of 3
EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2026

Summary:

Age-related macular degeneration (AMD) is a progressive eye condition that is characterized by the gradual deterioration of the macula, which is the area of the retina responsible for central vision. AMD is the most common cause of significant irreversible vision loss among the elderly (NEI, 2015; NHS, 2015). AMD is classified into three stages: early AMD, intermediate AMD, and late AMD. Early AMD is characterized by the presence of drusen (tiny yellow or white accumulations of extracellular material at the back of the eye) and/or focal pigmentary changes, both of which precede significant visual loss.

The total prevalent cases of AMD in the 7MM will increase from in the 7MM will increase from around 71 million cases in 2016 to almost 83 millioncases in 2026, at an Annual Growth Rate(AGR) of about 1.6% over the forecast period. Throughout the forecast period,Japan will have the highest number of total prevalent cases of AMD, followed by Italy.The total prevalent cases of AMD in Japan and Italy combined will make upapproximately39% of the total prevalent cases of AMD in the 7MM. epidemiologists attribute the growth in the total prevalent cases of AMD in the 7MM to the changing population demographics in the respective markets.

The diagnosed incident cases of AMD in the 7MM will increase from around 11.2 million cases in 2016 to nearly 13 million cases in 2026, at an AGR of almost 1.5%. Throughout the forecast period,Japan will have the highest number of diagnosed incident cases of AMD, followed by Italy.The diagnosed incident cases of AMD in Japan and Italy combined will make up approximately40% of the diagnosed incident cases of AMD in the 7MM. epidemiologists attribute the growth in the diagnosed incident cases of AMD in the 7MM to the changing population demographics in the respective markets.

The report 'EpiCast Report: Age-Related Macular Degeneration - Epidemiology Forecast to 2026', provides an overview of the risk factors, comorbidities, and the global and historical trends for AMD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).The reportalso includes a 10-year epidemiological forecast for the total prevalent cases of AMD, early AMD, late AMD, late dry AMD, and late wet AMD, all of which are segmented by sex and age (ages 50 years and older) in these markets.

Scope:
  • The Age-related Macular Degeneration (AMD) EpiCast Report provides an overview of the risk factors and global trends of AMD in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report also includes a 10-year epidemiological forecast for the total prevalent cases of AMD, early AMD, late AMD, late dry AMD, and late wet AMD, all of which are segmented by sex and age (ages 50 years and older) in these markets. epidemiologists also provided the diagnosed incident cases of AMD, early AMD, late AMD, late dry AMD, and late wet AMD, all of which are segmented by sex and age (ages 50 years and older). Additionally, the report includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed incident cases of large drusen (=125 µm) segmented by sex and age (ages 50 years and older) in these markets.
  • The AMD epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
  • The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.
Reasons to Purchase:

The AMD EpiCast report will allow you to -
  • Develop business strategies by understanding the trends shaping and driving the global AMD market.
  • Quantify patient populations in the global AMD market to improve product design, pricing, and launch plans.
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for AMD therapeutics in each of the markets covered.
  • Understand magnitude of AMD population by type.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1 Table of Contents
List of Tables
List of Figures

2 Age-Related Macular Degeneration: Executive Summary
2.1 Related Reports
2.2 Upcoming Reports

3 Epidemiology
3.1 Disease Background
3.2 Risk Factors and Comorbidities
3.3 Global and Historical Trends
3.4 Forecast Methodology
3.4.1 Sources
3.4.2 Forecast Assumptions and Methods
3.4.3 Total Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and Large Drusen
3.4.4 Diagnosed Incident Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and Large Drusen
3.5 Epidemiological Forecast for AMD (2016-2026)
3.5.1 Total Prevalent Cases of AMD
3.5.2 Age-Specific Total Prevalent Cases of AMD
3.5.3 Sex-Specific Total Prevalent Cases of AMD
3.5.4 Total Prevalent Cases of Early AMD
3.5.5 Total Prevalent Cases of Late AMD
3.5.6 Total Prevalent Cases of Late Dry AMD
3.5.7 Total Prevalent Cases of Late Wet AMD
3.5.8 Total Prevalent Cases of Large Drusen
3.5.9 Diagnosed Incident Cases of AMD
3.5.10 Age-Specific Diagnosed Incident Cases of AMD
3.5.11 Sex-Specific Diagnosed Incident Cases of AMD
3.5.12 Diagnosed Incident Cases of Early AMD
3.5.13 Diagnosed Incident Cases of Late AMD
3.5.14 Diagnosed Incident Cases of Late Dry AMD
3.5.15 Diagnosed Incident Cases of Late Wet AMD
3.5.16 Diagnosed Incident Cases of Large Drusen
3.6 Discussion
3.6.1 Epidemiological Forecast Insight
3.6.2 Limitations of the Analysis
3.6.3 Strengths of the Analysis

4 Appendix
4.1 Bibliography
4.2 About the Authors
4.2.1 Epidemiologist
4.2.2 Reviewers
4.2.3 Global Director of Therapy Analysis and Epidemiology
4.2.4 Global Head and EVP of Healthcare Operations and Strategy
4.3 About
4.4 Contact Us
4.5 Disclaimer

List of Tables:
Table 1: Risk Factors and Comorbid Conditions Associated with AMD
Table 2: Classification of AMD
Table 3: 7MM, Total Prevalent Cases of AMD, Both Sexes, Ages =50 Years, N, Selected Years 2016-2026
Table 4: 7MM, Total Prevalent Cases of Early AMD, Both Sexes, Ages =50 Years, N, Selected Years 2016-2026
Table 5: 7MM, Total Prevalent Cases of Late AMD, Both Sexes, Ages =50 Years, N, Selected Years 2016-2026
Table 6: 7MM, Total Prevalent Cases of Late Dry AMD, Both Sexes, Ages =50 Years, N, Selected Years 2016-2026
Table 7: 7MM, Total Prevalent Cases of Late Wet AMD, Both Sexes, N, Ages =50 Years, Selected Years 2016-2026
Table 8: 7MM, Total Prevalent Cases of Large Drusen, Both Sexes, Ages =50 Years, N, Selected Years 2016-2026
Table 9: 7MM, Diagnosed Incident Cases of AMD, Both Sexes, Ages =50 Years, N, Selected Years 2016-2026
Table 10: 7MM, Diagnosed Incident Cases of Early AMD, Both Sexes, Ages =50 Years, N, Selected Years 2016-2026
Table 11: 7MM, Diagnosed Incident Cases of Late AMD, Both Sexes, Ages =50 Years, N, Selected Years 2016-2026
Table 12: 7MM, Diagnosed Incident Cases of Late Dry AMD, Both Sexes, Ages =50 Years, N, Selected Years 2016-2026
Table 13: 7MM, Diagnosed Incident Cases of Late Wet AMD, Both Sexes, Ages =50 Years, N, Selected Years 2016-2026
Table 14: 7MM, Diagnosed Incident Cases of Large Drusen, Both Sexes, Ages =50 Years, N, Selected Years 2016-2026

List of Figures:
Figure 1: 7MM, Total Prevalent Cases of AMD, Both Sexes, Ages =50 Years, N, 2016 and 2026
Figure 2: 7MM, Diagnosed Incident Cases of AMD, Both Sexes, Ages =50 Years, N, 2016 and 2026
Figure 3: 7MM, Age-Standardized Total Prevalence of AMD (%), Men and Women, Ages =50 Years, 2016
Figure 4: 7MM, Sources Used, Total Prevalent Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and Large Drusen
Figure 5: 7MM, Sources Used, Diagnosed Incident Cases of AMD, Early AMD, Late AMD, Late Dry AMD, Late Wet AMD, and Large Drusen
Figure 6: 7MM, Age-Specific Total Prevalent Cases of AMD, Both Sexes, N, 2016
Figure 7: 7MM, Sex-Specific Total Prevalent Cases of AMD, Ages =50 Years, N, 2016
Figure 8: 7MM, Age-Specific Diagnosed Incident Cases of AMD, Both Sexes, N, 2016
Figure 9: 7MM, Sex-Specific Diagnosed Incident Cases of AMD, Ages =50 Years, N, 2016
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll